CYP450 pharmacogenetics for personalizing cancer therapy

Drug Resistance Updates

Volumn 11, Issue 3, 2008, Pages 77-98

  van Schaik, Ron H N ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CYP; Cytochrome P450; Oncology; Pharmacogenetics

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DOCETAXEL; ETOPOSIDE; GEFITINIB; IFOSFAMIDE; IMATINIB; IRINOTECAN; KETOCONAZOLE; PACLITAXEL; PHENYTOIN; TAMOXIFEN; TENIPOSIDE; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; CANCER THERAPY; CATALYSIS; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; ENDOMETRIUM CANCER; GENETIC POLYMORPHISM; GENOTOXICITY; GENOTYPE; HEREDITY; HUMAN; INDIVIDUALIZATION; LUNG EMBOLISM; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OXIDATIVE STRESS; PHARMACOGENETICS; PRIORITY JOURNAL; TERATOGENICITY; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 46149095280     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2008.03.002     Document Type: Article

References (183)

1. Agundez J.A., Ledesma M.C., Ladero J.M., and Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin. Pharmacol. Ther. 57 (1995) 265-269
2. Aklillu E., Persson I., Bertilsson L., Johansson I., Rodrigues F., and Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278 (1996) 441-446
3. Amirimani B., Ning B., Deitz A.C., Weber B.L., Kadlubar F.F., and Rebbeck T.R. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. 42 (2003) 299-305
4. Amirimani B., Walker A.H., Weber B.L., and Rebbeck T.R. RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 91 (1999) 1588-1590
5. Ando Y., Fuse E., and Figg W.D. Thalidomide metabolism by the CYP2C subfamily. Clin. Cancer Res. 8 (2002) 1964-1973
6. Ando Y., Price D.K., Dahut W.L., Cox M.C., Reed E., and Figg W.D. Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol. Ther. 1 (2002) 669-673
7. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 347 (2002) 481-487
8. Bahadur N., Leathart J.B., Mutch E., Steimel-Crespi D., Dunn S.A., Gilissen R., Houdt J.V., et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem. Pharmacol. 64 (2002) 1579-1589
9. Baker S.D., Li J., ten Tije A.J., Figg W.D., Graveland W., Verweij J., and Sparreboom A. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin. Pharmacol. Ther. 77 (2005) 43-53
10. Baker S.D., Sparreboom A., and Verweij J. Clinical pharmacokinetics of docetaxel: recent developments. Clin. Pharmacokinet. 45 (2006) 235-252
11. Baker, S.D., Verweij, J., Cusatis, G., van Schaik, R.H., Marsh, S., Orwick, S.J., Franke, R.M., et al., 2008. Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther., in press.
12. Baker S.D., Verweij J., Rowinsky E.K., Donehower R.C., Schellens J.H., Grochow L.B., and Sparreboom A. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J. Natl. Cancer Inst. 94 (2002) 1883-1888
13. Bauer K.S., Dixon S.C., and Figg W.D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. 55 (1998) 1827-1834
14. Bolton A.E., Peng B., Hubert M., Krebs-Brown A., Capdeville R., Keller U., and Seiberling M. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother. Pharmacol. 53 (2004) 102-106
15. Bonanni B., Macis D., Maisonneuve P., Johansson H.A., Gucciardo G., Oliviero P., Travaglini R., Muraca M.G., Rotmensz N., Veronesi U., and Decensi A.U. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J. Clin. Oncol. 24 (2006) 3708-3709 author reply 3709
16. Bosch T.M., Huitema A.D., Doodeman V.D., Jansen R., Witteveen E., Smit W.M., Jansen R.L., van Herpen C.M., Soesan M., Beijnen J.H., and Schellens J.H. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin. Cancer Res. 12 (2006) 5786-5793
17. Braun A.G., Harding F.A., and Weinreb S.L. Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol. Appl. Pharmacol. 82 (1986) 175-179
18. Braun A.G., and Weinreb S.L. Teratogen metabolism: spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes. Teratog. Carcinog. Mutagen. 5 (1985) 149-158
19. Brock N., Stekar J., Pohl J., Niemeyer U., and Scheffler G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung 29 (1979) 659-661
20. Buchdunger E., O'Reilly T., and Wood J. Pharmacology of imatinib (STI571). Eur. J. Cancer 38 Suppl. 5 (2002) S28-S36
21. Burchert A. Roots of imatinib resistance: a question of self-renewal?. Drug Resist. Updates 10 (2007) 152-161
22. Burk O., Tegude H., Koch I., Hustert E., Wolbold R., Glaeser H., et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem. 277 (2002) 24280-24288
23. Chang T.K., Weber G.F., Crespi C.L., and Waxman D.J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53 (1993) 5629-5637
24. m catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 7 (1997) 211-221
25. Chen C.S., Jounaidi Y., and Waxman D.J. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab. Dispos. 33 (2005) 1261-1267
26. Choi J.Y., Nowell S.A., Blanco J.G., and Ambrosone C.B. The role of genetic variability in drug metabolism pathways in breast cancer prognosis. Pharmacogenomics 7 (2006) 613-624
27. Chu W., Fyles A., Sellers E.M., McCready D.R., Murphy J., Pal T., and Narod S.A. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis 28 (2007) 2139-2142
28. Clark P.I., and Slevin M.L. The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinet. 12 (1987) 223-252
29. Clarke S.J., and Rivory L.P. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. 36 (1999) 99-114
30. Cohen M.H., Williams G., Johnson J.R., Duan J., Gobburu J., Rahman A., et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8 (2002) 935-942
31. Coller J.K., Krebsfaenger N., Klein K., Endrizzi K., Wolbold R., Lang T., et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br. J. Clin. Pharmacol. 54 (2002) 157-167
32. Cox P.J. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochem. Pharmacol. 28 (1979) 2045-2049
33. Cresteil T., Monsarrat B., Alvinerie P., Treluyer J.M., Vieira I., and Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res. 54 (1994) 386-392
34. Cresteil T., Monsarrat B., Dubois J., Sonnier M., Alvinerie P., and Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab. Dispos. 30 (2002) 438-445
35. Crewe H.K., Notley L.M., Wunsch R.M., Lennard M.S., and Gillam E.M. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 30 (2002) 869-874
36. Dahl M.L., Johansson I., Bertilsson L., Ingelman-Sundberg M., and Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population, analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274 (1995) 516-520
37. Dai D., Tang J., Rose R., Hodgson E., Bienstock R.J., Mohrenweiser H.W., and Goldstein J.A. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299 (2001) 825-831
38. Dai D., Zeldin D.C., Blaisdell J.A., Chanas B., Coulter S.J., Ghanayem B.I., and Goldstein J.A. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11 (2001) 597-607
39. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4082-4085
40. de Jong F.A., Marsh S., Mathijssen R.H., King C., Verweij J., Sparreboom A., and McLeod H.L. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. 10 (2004) 5889-5894
41. Dehal S.S., and Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 57 (1997) 3402-3406
42. Dennison J.B., Jones D.R., Renbarger J.L., and Hall S.D. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J. Pharmacol. Exp. Ther. 321 (2007) 553-563
43. Dennison J.B., Kulanthaivel P., Barbuch R.J., Renbarger J.L., Ehlhardt W.J., and Hall S.D. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab. Dispos. 34 (2006) 1317-1327
44. Desta Z., Ward B.A., Soukhova N.V., and Flockhart D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310 (2004) 1062-1075
45. Dickmann L.J., Rettie A.E., Kneller M.B., Kim R.B., Wood A.J., Stein C.M., Wilkinson G.R., and Schwarz U.I. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol. 60 (2001) 382-387
46. Ekins S., Vandenbranden M., Ring B.J., Gillespie J.S., Yang T.J., Gelboin H.V., and Wrighton S.A. Further characterization of the expression in liver and catalytic activity of CYP2B6. J. Pharmacol. Exp. Ther. 286 (1998) 1253-1259
47. Figg W.D., Dahut W., Duray P., Hamilton M., Tompkins A., Steinberg S.M., et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 7 (2001) 1888-1893
48. Floyd M.D., Gervasini G., Masica A.L., Mayo G., George Jr. A.L., Bhat K., Kim R.B., and Wilkinson G.R. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13 (2003) 595-606
49. Friedman H.S., Colvin O.M., Aisaka K., Popp J., Bossen E.H., Reimer K.A., et al. Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res. 50 (1990) 2455-2462
50. Frost B.M., Lonnerholm G., Koopmans P., Abrahamsson J., Behrendtz M., Castor A., Forestier E., Uges D.R., and de Graaf S.S. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr. 92 (2003) 551-557
51. Frye R.F., Fitzgerald S.M., Lagattuta T.F., Hruska M.W., and Egorin M.J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther. 76 (2004) 323-329
52. Fujita K. Cytochrome P450 and anticancer drugs. Curr. Drug Metab. 7 (2006) 23-37
53. Fujita K., and Sasaki Y. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug. Metab. 8 (2007) 554-562
54. Gardner E.R., Burger H., van Schaik R.H., van Oosterom A.T., de Bruijn E.A., Guetens G., Prenen H., de Jong F.A., Baker S.D., Bates S.E., Figg W.D., Verweij J., Sparreboom A., and Nooter K. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin. Pharmacol. Ther. 80 (2006) 192-201
55. Gellner K., Eiselt R., Hustert E., Arnold H., Koch I., Haberl M., et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11 (2001) 111-121
56. Gervot L., Rochat B., Gautier J.C., Bohnenstengel F., Kroemer H., de Berardinis V., Martin H., Beaune P., and de Waziers I. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9 (1999) 295-306
57. Goetz M.P., Knox S.K., Suman V.J., Rae J.M., Safgren S.L., Ames M.M., et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101 (2007) 113-121
58. Goetz M.P., Rae J.M., Suman V.J., Safgren S.L., Ames M.M., Visscher D.W., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23 (2005) 9312-9318
59. Goh B.C., Lee S.C., Wang L.Z., Fan L., Guo J.Y., Lamba J., Schuetz E., et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20 (2002) 3683-3690
60. Goldstein J.A., and de Morais S.M. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4 (1994) 285-299
61. Goldstein J.A., Ishizaki T., Chiba K., de Morais S.M., Bell D., Krahn P.M., and Evans D.A. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7 (1997) 59-64
62. Griskevicius L., Yasar U., Sandberg M., Hidestrand M., Eliasson E., Tybring G., Hassan M., and Dahl M.L. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur. J. Clin. Pharmacol. 59 (2003) 103-109
63. Haaz M.C., Riche C., Rivory L.P., and Robert J. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy camptothecine] by human hepatic microsomes. Drug. Metab. Dispos. 26 (1998) 769-774
64. Haaz M.C., Rivory L., Riche C., Vernillet L., and Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res. 58 (1998) 468-472
65. Harris J.W., Rahman A., Kim B.R., Guengerich F.P., and Collins J.M. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54 (1994) 4026-4035
66. Hatfill S.J., Fester E.D., de Beer D.P., and Bohm L. Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites. Leuk Res. 15 (1991) 129-136
67. Henningsson A., Karlsson M.O., Vigano L., Gianni L., Verweij J., and Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J. Clin. Oncol. 19 (2001) 4065-4073
68. Henningsson A., Marsh S., Loos W.J., Karlsson M.O., Garsa A., Mross K., Mielke S., Vigano L., Locatelli A., Verweij J., Sparreboom A., and McLeod H.L. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin. Cancer Res. 11 (2005) 8097-8104
69. Hesselink D.A., van Schaik R.H., van der Heiden I.P., van der Werf M., Gregoor P.J., Lindemans J., Weimar W., and van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74 (2003) 245-254
70. Hiratsuka M., Takekuma Y., Endo N., Narahara K., Hamdy S.I., Kishikawa Y., Matsuura M., Agatsuma Y., Inoue T., and Mizugaki M. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur. J. Clin. Pharmacol. 58 (2002) 417-421
71. Hsieh K.P., Lin Y.Y., Cheng C.L., Lai M.L., Lin M.S., Siest J.P., and Huang J.D. Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos. 29 (2001) 268-273
72. Huang Z., Roy P., and Waxman D.J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 59 (2000) 961-972
73. Hustert E., Haberl M., Burk O., Wolbold R., He Y.Q., Klein K., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11 (2001) 773-779
74. Ieiri I., Tainaka H., Morita T., Hadama A., Mamiya K., Hayashibara M., et al. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther. Drug Monit. 22 (2000) 237-244
75. Imai J., Ieiri I., Mamiya K., Miyahara S., Furuumi H., Nanba E., et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10 (2000) 85-89
76. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom. J. 5 (2005) 6-13
77. Ingelman-Sundberg M., Sim S.C., Gomez A., and Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116 (2007) 496-526
78. Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.H., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97 (2005) 30-39
79. Jinno H., Tanaka-Kagawa T., Ohno A., Makino Y., Matsushima E., Hanioka N., and Ando M. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos. 31 (2003) 398-403
80. Johansson I., Lundqvist E., Bertilsson L., Dahl M.L., Sjoqvist F., and Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 11825-11829
81. Judson I., Ma P., Peng B., Verweij J., Racine A., di Paola E.D., van Glabbeke M., Dimitrijevic S., Scurr M., Dumez H., and van Oosterom A. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time, EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol. 55 (2005) 379-386
82. Kaijser G.P., Korst A., Beijnen J.H., Bult A., and Underberg W.J. The analysis of ifosfamide and its metabolites (review). Anticancer Res. 13 (1993) 1311-1324
83. Kawashiro T., Yamashita K., Zhao X.J., Koyama E., Tani M., Chiba K., and Ishizaki T. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J. Pharmacol. Exp. Ther. 286 (1998) 1294-1300
84. Kirchheiner J., and Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77 (2005) 1-16
85. Kirchheiner J., Klein C., Meineke I., Sasse J., Zanger U.M., Murdter T.E., Roots I., and Brockmoller J. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13 (2003) 619-626
86. Kishi S., Yang W., Boureau B., Morand S., Das S., Chen P., Cook E.H., Rosner G.L., Schuetz E., Pui C.H., and Relling M.V. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103 (2004) 67-72
87. Komoroski B.J., Parise R.A., Egorin M.J., Strom S.C., and Venkataramanan R. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin. Cancer Res. 11 (2005) 6972-6979
88. Kramer, M.A., Rettie, A.E., Rieder, M.J., Cabacungan, E.T., Hines, R.N., 2008. Novel CYP2C9 promoter variants and assessment of their impact on gene expression. Mol. Pharmacol., Epub ahead of print.
89. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27 (2001) 383-391
90. Kumar G., Ray S., Walle T., Huang Y., Willingham M., Self S., and Bhalla K. Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol. Cancer Chemother. Pharmacol. 36 (1995) 129-135
91. Lamba J.K., Lin Y.S., Schuetz E.G., and Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54 (2002) 1271-1294
92. Lamba J.K., Lin Y.S., Thummel K., Daly A., Watkins P.B., Strom S., Zhang J., and Schuetz E.G. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12 (2002) 121-132
93. Lamba V., Lamba J., Yasuda K., Strom S., Davila J., Hancock M.L., et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. 307 (2003) 906-922
94. Lang T., Klein K., Fischer J., Nussler A.K., Neuhaus P., Hofmann U., Eichelbaum M., Schwab M., and Zanger U.M. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11 (2001) 399-415
95. Lange B.J., Bostrom B.C., Cherlow J.M., Sensel M.G., La M.K., Rackoff W., Heerema N.A., Wimmer R.S., Trigg M.E., and Sather H.N. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99 (2002) 825-833
96. Lee C.R., Pieper J.A., Hinderliter A.L., Blaisdell J.A., and Goldstein J.A. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. Clin. Pharmacol. Ther. 72 (2002) 562-571
97. Maitland M.L., Vasisht K., and Ratain M.J. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?. Trends Pharmacol. Sci. 27 (2006) 432-437
98. Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin. Drug Safety 2 (2003) 597-607
99. Mathijssen R.H., de Jong F.A., van Schaik R.H., Lepper E.R., Friberg L.E., Rietveld T., et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J. Natl. Cancer Inst. 96 (2004) 1585-1592
100. Mathijssen R.H., Marsh S., Karlsson M.O., Xie R., Baker S.D., Verweij J., Sparreboom A., and McLeod H.L. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. 9 (2003) 3246-3253
101. Mathijssen R.H., and van Schaik R.H. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment. Eur. J. Cancer 42 (2006) 141-148
102. Mathijssen R.H., Verweij J., de Jonge M.J., Nooter K., Stoter G., and Sparreboom A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J. Clin. Oncol. 20 (2002) 81-87
103. McCune J.S., and Lindley C. Appropriateness of maximum-dose guidelines for vincristine. Am. J. Health Syst. Pharm. 54 (1997) 1755-1758
104. McKillop D., McCormick A.D., Millar A., Miles G.S., Phillips P.J., and Hutchison M. Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 35 (2005) 39-50
105. McLellan R.A., Oscarson M., Seidegard J., Evans D.A., and Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7 (1997) 187-191
106. Meyer U.A. Genotype or phenotype: the definition of a pharmacogenetic polymorphism. Pharmacogenetics 1 (1991) 66-67
107. Mross K., Hollander N., Hauns B., Schumacher M., and Maier-Lenz H. The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother. Pharmacol. 45 (2000) 463-470
108. Nakajima M., Fujiki Y., Kyo S., Kanaya T., Nakamura M., Maida Y., Tanaka M., Inoue M., and Yokoi T. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J. Clin. Pharmacol. 45 (2005) 674-682
109. Nakajima M., Fujiki Y., Noda K., Ohtsuka H., Ohkuni H., Kyo S., Inoue M., Kuroiwa Y., and Yokoi T. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab. Dispos. 31 (2003) 687-690
110. Nakajima Y., Yoshitani T., Fukushima-Uesaka H., Saito Y., Kaniwa N., Kurose K., et al. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin. Pharmacol. Ther. 80 (2006) 179-191
111. Nicolai S., Sies H., and Stahl W. Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts. Biochem. Pharmacol. 53 (1997) 1553-1557
112. Novartis, 2003. Gleevec. www.fda.gov/cder/approval/index.htm NDA 21-588/S002.
113. Nowell S.A., Ahn J., Rae J.M., Scheys J.O., Trovato A., Sweeney C., MacLeod S.L., Kadlubar F.F., and Ambrosone C.B. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treatm. 91 (2005) 249-258
114. Pasquier E., Honoré S., and Braguer D. Microtubule-targeting agents in angiogenesis: where do we stand?. Drug Resist. Updates 9 (2006) 74-86
115. Peng B., Lloyd P., and Schran H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet. 44 (2005) 879-894
116. Petros W.P., Broadwater G., Berry D., Jones R.B., Vredenburgh J.J., Gilbert C.J., Gibbs J.P., Colvin O.M., and Peters W.P. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin. Cancer Res. 8 (2002) 698-705
117. Petros W.P., Hopkins P.J., Spruill S., Broadwater G., Vredenburgh J.J., Colvin O.M., Peters W.P., Jones R.B., Hall J., and Marks J.R. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J. Clin. Oncol. 23 (2005) 6117-6125
118. Pollock B.H., DeBaun M.R., Camitta B.M., Shuster J.J., Ravindranath Y., Pullen D.J., Land V.J., Mahoney Jr. D.H., Lauer S.J., and Murphy S.B. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J. Clin. Oncol. 18 (2000) 813-823
119. Puisset F., Chatelut E., Dalenc F., Busi F., Cresteil T., Azema J., Poublanc M., Hennebelle I., Lafont T., Chevreau C., and Roche H. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother. Pharmacol. 54 (2004) 265-272
120. Puisset F., Chatelut E., Sparreboom A., Delord J.P., Berchery D., Lochon I., Lafont T., and Roche H. Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect. Cancer Chemother. Pharmacol. 60 (2007) 305-308
121. Rahman A., Korzekwa K.R., Grogan J., Gonzalez F.J., and Harris J.W. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54 (1994) 5543-5546
122. Rebbeck T.R., Jaffe J.M., Walker A.H., Wein A.J., and Malkowicz S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 90 (1998) 1225-1229
123. Relling M.V., Evans R., Dass C., Desiderio D.M., and Nemec J. Human cytochrome P450 metabolism of teniposide and etoposide. J. Pharmacol. Exp. Ther. 261 (1992) 491-496
124. Relling M.V., Nemec J., Schuetz E.G., Schuetz J.D., Gonzalez F.J., and Korzekwa K.R. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol. Pharmacol. 45 (1994) 352-358
125. Ren S., Yang J.S., Kalhorn T.F., and Slattery J.T. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res. 57 (1997) 4229-4235
126. Rodriguez-Antona C., and Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 25 (2006) 1679-1691
127. Rodriguez-Novoa S., Barreiro P., Rendon A., Jimenez-Nacher I., Gonzalez-Lahoz J., and Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin. Infect. Dis. 40 (2005) 1358-1361
128. Rotger M., Colombo S., Furrer H., Bleiber G., Buclin T., Lee B.L., Keiser O., Biollaz J., Decosterd L., and Telenti A. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genom. 15 (2005) 1-5
129. Sachse C., Brockmoller J., Bauer S., and Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60 (1997) 284-295
130. Saitoh A., Sarles E., Capparelli E., Aweeka F., Kovacs A., Burchett S.K., Wiznia A., Nachman S., Fenton T., and Spector S.A. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. Aids 21 (2007) 2191-2199
131. Santos A., Zanetta S., Cresteil T., Deroussent A., Pein F., Raymond E., et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res. 6 (2000) 2012-2020
132. Sata F., Sapone A., Elizondo G., Stocker P., Miller V.P., Zheng W., Raunio H., Crespi C.L., and Gonzalez F.J. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67 (2000) 48-56
133. Schenk P.W., van Fessem M.A., Verploegh-Van Rij S., Mathot R.A., van Gelder T., Vulto A.G., van Vliet M., Lindemans J., Bruijn J.A., and van Schaik R.H. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol. Psychiatry (2007) Epub ahead of print
134. Schirmer M., Toliat M.R., Haberl M., Suk A., Kamdem L.K., Klein K., Brockmoller J., Nurnberg P., Zanger U.M., and Wojnowski L. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenet. Genom. 16 (2006) 59-71
135. Schmidt M., and Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist. Updates 10 (2007) 162-181
136. Schroth W., Antoniadou L., Fritz P., Schwab M., Muerdter T., Zanger U.M., Simon W., Eichelbaum M., and Brauch H. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25 (2007) 5187-5193
137. Schumacher H., Smith R.L., and Williams R.T. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. Chemother. 25 (1965) 324-337
138. Scordo M.G., Spina E., Facciola G., Avenoso A., Johansson I., and Dahl M.L. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl.) 147 (1999) 300-305
139. Shou M., Martinet M., Korzekwa K.R., Krausz K.W., Gonzalez F.J., and Gelboin H.V. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8 (1998) 391-401
140. Sim S.C., Risinger C., Dahl M.L., Aklillu E., Christensen M., Bertilsson L., and Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79 (2006) 103-113
141. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341 (1999) 1565-1571
142. Sladek N.E. Metabolism of oxazaphosphorines. Pharmacol. Ther. 37 (1988) 301-355
143. Smit P., van Schaik R.H., van der Werf M., van den Beld A.W., Koper J.W., Lindemans J., et al. A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J. Clin. Endocrinol. Metab. 90 (2005) 5313-5316
144. Smith N.F., Figg W.D., and Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol. In Vitro 20 (2006) 163-175
145. Smith P.F., Bullock J.M., Booker B.M., Haas C.E., Berenson C.S., and Jusko W.J. Induction of imatinib metabolism by hypericum perforatum. Blood 104 (2004) 1229-1230
146. Sonnichsen D.S., Liu Q., Schuetz E.G., Schuetz J.D., Pappo A., and Relling M.V. Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther. 275 (1995) 566-575
147. Soyama A., Saito Y., Hanioka N., Murayama N., Nakajima O., Katori N., Ishida S., Sai K., Ozawa S., and Sawada J.I. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull. 24 (2001) 1427-1430
148. Soyama A., Saito Y., Komamura K., Ueno K., Kamakura S., Ozawa S., and Sawada J. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame shift. Drug Metab. Pharmacokin. 17 (2002) 374-377
149. Spratlin J., and Sawyer M.B. Pharmacogenetics of paclitaxel metabolism. Crit. Rev. Oncol. Hematol. 61 (2007) 222-229
150. Spurdle A.B., Goodwin B., Hodgson E., Hopper J.L., Chen X., Purdie D.M., McCredie M.R., Giles G.G., Chenevix-Trench G., and Liddle C. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12 (2002) 355-366
151. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95 (2003) 1758-1764
152. Steimer W., Zopf K., von Amelunxen S., Pfeiffer H., Bachofer J., Popp J., et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem. 50 (2004) 1623-1633
153. Swaisland H.C., Cantarini M.V., Fuhr R., and Holt A. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin. Pharmacokinet. 45 (2006) 633-644
154. Takada K., Arefayene M., Desta Z., Yarboro C.H., Boumpas D.T., Balow J.E., Flockhart D.A., and Illei G.G. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 50 (2004) 2202-2210
155. Timm R., Kaiser R., Lotsch J., Heider U., Sezer O., Weisz K., et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenom. J. 5 (2005) 365-373
156. Tortora G., Bianco R., Daniele G., Ciardello F., McCubrey J.A., Ricciardi M.R., et al. Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematological malignancies. Drug Resist. Updates 10 (2007) 81-100
157. Tran A., Jullien V., Alexandre J., Rey E., Rabillon F., Girre V., et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin. Pharmacol. Ther. 79 (2006) 570-580
158. Tsuchiya K., Gatanaga H., Tachikawa N., Teruya K., Kikuchi Y., Yoshino M., et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun. 319 (2004) 1322-1326
159. van den Berg H.W., Desai Z.R., Wilson R., Kennedy G., Bridges J.M., and Shanks R.G. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother. Pharmacol. 8 (1982) 215-219
160. van Maanen J.M., de Ruiter C., de Vries J., Kootstra P.R., Gobas F., and Pinedo H.M. The role of metabolic activation by cytochrome P-450 in covalent binding of VP 16-213 to rat liver and HeLa cell microsomal proteins. Eur. J. Cancer Clin. Oncol. 21 (1985) 1099-1106
161. van Maanen J.M., de Vries J., Pappie D., van den Akker E., Lafleur V.M., Retel J., van der Greef J., and Pinedo H.M. Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer Res. 47 (1987) 4658-4662
162. van Schaik R.H. Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents. Ther. Drug Monit. 26 (2004) 236-240
163. van Schaik R.H. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest. New Drugs 23 (2005) 513-522
164. van Schaik R.H., de Wildt S.N., van Iperen N.M., Uitterlinden A.G., van den Anker J.N., and Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin. Chem. 46 (2000) 1834-1836
165. van Schaik R.H., van der Heiden I.P., van den Anker J.N., and Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin. Chem. 48 (2002) 1668-1671
166. van Schaik R.H.N., van der Werf M., van der Heiden I.P., Dorrestein S., Brosens R., Thiadens A., et al. CYP3A4, CYP3A5 and MDR-1 variant alleles in the Dutch Caucasian population. Clin. Pharmacol. Ther. 73 (2003) 42
167. Verweij J., Judson I., and van Oosterom A. STI571: a magic bullet?. Eur. J. Cancer. 37 (2001) 1816-1819
168. Walker A.H., Jaffe J.M., Gunasegaram S., Cummings S.A., Huang C.S., Chern H.D., et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum. Mutat. 12 (1998) 289
169. Walker D., Flinois J.P., Monkman S.C., Beloc C., Boddy A.V., Cholerton S., et al. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol. 47 (1994) 1157-1163
170. Wang J., Sonnerborg A., Rane A., Josephson F., Lundgren S., Stahle L., and Ingelman-Sundberg M. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genom. 16 (2006) 191-198
171. Wegman P., Vainikka L., Stal O., Nordenskjold B., Skoog L., Rutqvist L.E., and Wingren S. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7 (2005) R284-R290
172. Westlind-Johnsson A., Hermann R., Huennemeyer A., Hauns B., Lahu G., Nassr N., et al. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin. Pharmacol. Ther. 79 (2006) 339-349
173. White I.N. Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr. Drug Metab. 4 (2003) 223-239
174. Wyen C., Hendra H., Vogel M., Hoffmann C., Knechten H., Brockmeyer N.H., et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J. Antimicrob. Chemother. 61 (2008) 914-918
175. Xie H., Griskevicius L., Stahle L., Hassan Z., Yasar U., Rane A., et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur. J. Pharm. Sci. 27 (2006) 54-61
176. Xie H.G., Prasad H.C., Kim R.B., and Stein C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54 (2002) 1257-1270
177. Xie H.G., Wood A.J., Kim R.B., Stein C.M., and Wilkinson G.R. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5 (2004) 243-272
178. Xie H.J., Yasar U., Lundgren S., Griskevicius L., Terelius Y., Hassan M., and Rane A. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenom. J. 3 (2003) 53-61
179. Yamamoto N., Tamura T., Murakami H., Shimoyama T., Nokihara H., Ueda Y., et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J. Clin. Oncol. 23 (2005) 1061-1069
180. Zhang J., Tian Q., Chan S.Y., Duan W., and Zhou S. Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resist. Updates 8 (2005) 271-297
181. Zhao F., Loke C., Rankin S.C., Guo J.Y., Lee H.S., Wu T.S., et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 76 (2004) 210-219
182. Zhuo X., Zheng N., Felix C.A., and Blair I.A. Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab. Dispos. 32 (2004) 993-1000
183. Zineh I., Beitelshees A.L., Gaedigk A., Walker J.R., Pauly D.F., Eberst K., Leeder J.S., Phillips M.S., Gelfand C.A., and Johnson J.A. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin. Pharmacol. Ther. 76 (2004) 536-544